Coral Laboratories Limited
Coral Laboratories Limited Fundamental Analysis
Coral Laboratories Limited (CORALAB.BO) shows moderate financial fundamentals with a PE ratio of 11.03, profit margin of 15.97%, and ROE of 6.83%. The company generates $0.9B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 61.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze CORALAB.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakCORALAB.BO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCORALAB.BO trades at attractive valuation levels.
Growth Score
ModerateCORALAB.BO shows steady but slowing expansion.
Financial Health Score
ExcellentCORALAB.BO maintains a strong and stable balance sheet.
Profitability Score
WeakCORALAB.BO struggles to sustain strong margins.
Key Financial Metrics
Is CORALAB.BO Expensive or Cheap?
P/E Ratio
CORALAB.BO trades at 11.03 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CORALAB.BO's PEG of -0.57 indicates potential undervaluation.
Price to Book
The market values Coral Laboratories Limited at 0.72 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 8.37 times EBITDA. This is generally considered low.
How Well Does CORALAB.BO Make Money?
Net Profit Margin
For every $100 in sales, Coral Laboratories Limited keeps $15.97 as profit after all expenses.
Operating Margin
Core operations generate 10.96 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.83 in profit for every $100 of shareholder equity.
ROA
Coral Laboratories Limited generates $6.01 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Coral Laboratories Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Coral Laboratories Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
CORALAB.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
11.03
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.57
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.72
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.76
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.004
vs 25 benchmark
Current Ratio
Current assets to current liabilities
10.03
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How CORALAB.BO Stacks Against Its Sector Peers
| Metric | CORALAB.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 11.03 | 29.45 | Better (Cheaper) |
| ROE | 6.83% | 779.00% | Weak |
| Net Margin | 15.97% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 10.03 | 4.65 | Strong Liquidity |
| ROA | 6.01% | -19344.00% (disorted) | Weak |
CORALAB.BO outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Coral Laboratories Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation